Organon & Co. (OGN) Comparison with companies in other sectors?

Organon & Co. has a share price of 259.96M. You can analyze Organon & Co. (OGN) competitors across different market sectors through stock heatmaps.

What are OGN's NET and operating margins?

Organon & Co. (OGN) operating margin is around 0.22, and net profit margin is approximately 0.12 as of the latest reports.

In what way does OGN's earnings per share (EPS) trend reflect its financial momentum?

Organon & Co. (OGN) EPS is 2.88 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Organon & Co. is 3.55, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Organon & Co.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Organon & Co. like P/E which is 3.49, P/B which is 4.84, and PEG which is -0.26. Compare them with sector averages to evaluate if the stock is priced fairly.

Organon & Co.

OGN•NYSE

Healthcare

Drug Manufacturers - General

$10.21

$0.14(1.39%)

Fundamental Analysis of Organon & Co. (OGN)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$2.88

P/E Ratio

3.55

ROE

1.82%

Net Margin

0.12%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$2.65B

Shares OutstandingTotal number of shares issued

$259.96M

Book Value/ShareNet worth per share

$2.10

Revenue/ShareAnnual revenue per share

$24.41

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$2.88

Net MarginNet income as percentage of revenue

11.92%

Operating MarginOperating income as percentage of revenue

22.20%

ROEReturn on shareholders' equity

181.71%

ROAReturn on total assets

5.70%

ROCEReturn on capital employed

13.25%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$2.27

Cash/ShareCash and equivalents per share

$2.12

FCF YieldFree cash flow as percentage of market cap

22.13%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.86

Dividend YieldAnnual dividend as percentage of stock price

8.44%

Financial Ratios Analysis data is not available for OGNFinancial Ratios Analysis details for OGN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for OGNSector Benchmarking details for OGN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Organon & Co. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Organon & Co.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Organon & Co.'s unique business strengths and challenges.

Key Financial Metrics for Organon & Co.

For Organon & Co., essential financial indicators include EPS 2.88, PE 3.55, and ROE 1.82. These key ratios reveal insights into Organon & Co.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Organon & Co. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Organon & Co.

Metrics like Net Margin 11.92% and ROA 5.70% shed light on how well Organon & Co. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Organon & Co. can sustain its operations and continue growing in the future.

Valuation and Market Position of Organon & Co.

Using ratios such as P/B Ratio 4.84 and PEG Ratio -0.26, investors can assess whether Organon & Co. is appropriately valued based on its financials and growth potential. These figures, combined with Organon & Co.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Organon & Co.

Financial health indicators, such as Debt/Equity Ratio 16.52 and Cash Flow $2.27, provide a snapshot of Organon & Co.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Organon & Co., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Organon & Co.

Investing in Organon & Co. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Organon & Co. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;